Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market and other conditions, with the potential for underwriters to purchase an additional 15% of shares. This move follows Kura's effective shelf registration statement, providing for a streamlined public offering process.
SVB Leerink, Cowen, and Credit Suisse are acting as joint bookrunning managers. The exact size and terms of the offering remain uncertain, emphasizing significant market conditions.
Kura Oncology reported Q1 2020 financials, with a net loss of $19.2 million, increasing from $13.9 million in Q1 2019. The company holds $216.9 million in cash, providing operational leverage for upcoming developments. Kura plans to emphasize its farnesyl transferase inhibitor, tipifarnib, for HRAS mutant HNSCC and the menin inhibitor, KO-539, for NPM1-mutant AML. Three abstracts on tipifarnib will be presented at ASCO 2020. Notably, development of the ERK inhibitor, KO-947, has been terminated to focus on more promising programs.
Summary not available.